Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
America Great Health (AAGH)
Alhambra, CA, US
Operating as a U.S.-based biotechnology company, America Great Health (AAGH) focuses on two primary areas: the research and development of protein and peptide small molecular drugs, and the manufacturing and sale of a diverse portfolio including AI cloud computing-driven diagnostic and medical devices, cell therapies, regenerative medicine, and supplements. The company, which originated as Crown Marketing, adopted the name America Great Health in March 2017. Established in 2013, AAGH's headquarters are located in Alhambra, California.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | +0.00% | +0.00% | +9,900.00% | +0.00% | -91.67% | -75.00% | -99.31% | -78.63% | -99.78% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
-
Revenue growth Biotechnology: +1.6%+32.9% ★ Q2'25: +9.3% (vs Q2'24)
-
EPS growth Biotechnology: +29.7%+100.0% ★ Q2'25: +100.0% (vs Q2'24)
-
FCF margin FCF growth · Biotechnology: +16.2%-11.4% Q2'25: -260.8% (vs Q2'24)
-
EBIT margin Biotechnology: +0.0%+0.0% Q2'25: +264.7% (vs Q2'24)
-
ROIC Biotechnology: -16.1%— Q2'25: -36.6% (vs Q2'24)
-
Share dilution Biotechnology: -3.4%+0.1% ★ Q2'25: +0.1% (vs Q2'24)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-7.43× Q2'25: -6.06× (vs Q2'24)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-19 | C- | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Mike Qingkun Wang | Chief Executive Officer, President, Chief Financial Officer, Secretary & Chairman of the Board | 54.0K | male |
| David Liu | Chief Operating Officer | — | male |
| David Tsai | Chief Scientist | — | — |
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for AAGH
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
